Brief: Arch Scientists Publish Data On The Mechanism Of Action And Efficacy Of Lead Drug Candidate Lsalt Peptide In The Prevention Of Acute Kidney Injury
03/02/2022 13:18
Feb 3 (Reuters) - Arch Biopartners Inc ARCH.V :
* ARCH SCIENTISTS PUBLISH DATA ON THE MECHANISM OF ACTION
AND
EFFICACY OF LEAD DRUG CANDIDATE LSALT PEPTIDE IN THE PREVENTION
OF ACUTE KIDNEY INJURY
Source text for Eikon: ID:nGNXc176YY
Further company coverage: ARCH.V
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Arch Biopartners
See all newsBrief: Arch Biopartners To Expand Phase Ii Cardiac Surgery-Associated Acute Kidney Injury Trial To The US
Brief: Arch Biopartners Closes Non-Brokered Private Placement
Brief: Arch Strengthens Its Position As A Leading Kidney Therapeutics Company With The Acquisition Of A Breakthrough Platform To Develop New Drugs Targeting Chronic Kidney Disease (Ckd)
Brief: Arch Biopartners Closes Non-Brokered Private Placement
Brief: Arch Biopartners Announces Ontario Research Ethics Board Approval To Start Phase II Trial For LSALT Peptide